Internal medicine

Adverse effect

Clinical endpoint

Hepatocellular carcinoma

Biosimilar

Gastroenterology

Oncology

Chemotherapy

Bevacizumab

Sorafenib

Response Evaluation Criteria in Solid Tumors

Phases of clinical research

Clinical trial

Medicine

The Lancet Oncology

Sintilimab plus IBI305 showed a significant overall survival and progression-free survival benefit versus sorafenib in the first-line setting for Chinese patients with unresectable, HBV-associated hepatocellular carcinoma, with an acceptable safety profile. This combination regimen could provide a novel treatment option for such patients.

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study